萬孚生物(300482.SZ):董事會提議向下修正可轉債的轉股價
格隆匯1月21日丨萬孚生物(300482.SZ)公佈,為優化公司資本結構,維護投資者權益,支持公司長期發展,公司於2022年1月21日召開第四屆董事會第八次會議,審議通過了《關於董事會提議向下修正可轉換公司債券轉股價格的議案》,並提交公司2022年第一次臨時股東大會審議表決。
修正後的轉股價格應不低於該次股東大會召開日前二十個交易日公司股票交易均價和前一交易日均價之間的較高者且同時不得低於最近一期經審計的每股淨資產以及股票面值。同時,提請股東大會授權董事會根據《募集説明書》相關條款的規定,確定本次修正後的轉股價格、生效日期以及其他必要事項,並全權辦理相關手續,授權有效期自股東大會審議通過之日起至修正相關工作完成之日止。若本次股東大會召開日前二十個交易日公司股票交易均價和前一交易日均價之間的較高者高於調整前“萬孚轉債”的轉股價格(即71.65元/股),則“萬孚轉債”轉股價格無需調整。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.